Cxcr2 Inhibition Inhibits Metastasis and Prolongs Survival in KPC Mice
(A) Kaplan-Meier analysis of KPC mice treated from 10 weeks of age with scrambled pepducin (n = 15), gemcitabine (n = 14), CXCR2-inhibiting pepducin (n = 20), or CXCR2-inhibiting pepducin + gemcitabine (n = 11). p Values, log rank test.
(B) Table comparing incidence of metastases in KPC mice treated as indicated. p Values, chi-square test.
(C and D) H&E staining and IHC for MPO, F4/80, CD3, and tenascin C (TNC) in tumors in response to (C) scrambled pepducin and (D) CXCR2-targeting pepducin. See also Figure S4.